COVID-19 та постковідний синдром у фокусі ускладнень: рекомендації для лікарів: COVID-19: вияви з боку шлунково-кишкового тракту. Постковідний синдром при захворюваннях печінки

О. Є. Гріднєв; Г. Д. Фадєєнко

doi:10.30978/MG-2022-1-20

Автор(и)

О. Є. Гріднєв ДУ «Національний інститут терапії імені Л. Т. Малої НАМН України», Харків, Ukraine
Г. Д. Фадєєнко ДУ «Національний інститут терапії імені Л. Т. Малої НАМН України», Харків, Ukraine

DOI:

https://doi.org/10.30978/MG-2022-1-20

Анотація

-

Біографії авторів

О. Є. Гріднєв, ДУ «Національний інститут терапії імені Л. Т. Малої НАМН України», Харків

д. мед. н., ст. наук. співр., пров. наук. співр. відділу вивчення захворювань органів травлення і їх коморбідності з неінфекційними захворюваннями

Г. Д. Фадєєнко, ДУ «Національний інститут терапії імені Л. Т. Малої НАМН України», Харків

чл.-кор. НАМН України, д. мед. н., проф.,
директор Національного інституту терапії ім. Л. Т. Малої НАМН України,
зав. відділу вивчення захворювань органів травлення і їхньої коморбідності з неінфекційними захворюваннями

Посилання

Brenner E. J., Ungaro R. C., Gearry R. B. et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID‑19 outcomes in patients with inflammatory bowel diseases: results from an International Registry // Gastroenterology. — 2020. — 159. — P. 481 — 491. e3.

British Society of Gastroenterology expanded consensus advice for the management of IBD during the COVID‑19 pandemic. URL: https://www.bsg.org.uk/covid-19-advice/bsg-advice-for-management-of-inflammatory-bowel-diseases-during-the-covid-19-pandemic.

Burgueño J. F., Reich A., Hazime H. et al. Expression of SARS‑CoV‑2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD // Inflamm. Bowel Dis. — 2020. — 26. — P. 797.

Chen L., Lou J., Bai Y. et al. COVID‑19 Disease with positive fecal and negative pharyngeal and sputum viral tests // The American Journal of Gastroenterology: March 20, 2020. — Volume Publish Ahead of Print.

Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis // J. Med Virol. — 2020. — 92 (4). — P. 418 — 23.

Cheung K. S., Ivan F. N., Hung M. D. et al. Gastrointestinal manifestations of SARS‑CoV‑2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis // Gastroenterology. — 2020. — 159 (1). — P. 81 — 95.

Di Renzo L., Merra G., Esposito E., De Lorenzo A. Are probiotics effective adjuvant therapeutic choice in patients with COVID‑19? // Eur. Rev. Med. Pharmacol. Sci. — 2020. — 24 (8). — P. 4062 — 3.

Fang D., Ma J.-D., Guan J.-L. et al. A single-center, descriptive study on the digestive system of COVID‑19 in patients in wuhan. Chinese J. Digest. — 2020. — 40. — E005–E005.

Gadiparthi C., Perisetti A., Sayana H. et al. Gastrointestinal bleeding in patients with severe SARS‑CoV‑2. Am. J. Gastroenterol. 2020 Aug;115 (8). — P. 1283 — 5.

Gao Q. Y., Chen Y. X., Fang J. Y. 2019 Novel coronavirus infection and gastrointestinal tract // J. Dig. Dis. — 2020. — 21 (3). — P. 125 — 6.

Garg M., Burrell L. M., Velkoska E. et al. Up regulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: a pilot study. J. Renin Angiotensin Aldosterone Syst. 2015. — 16. — P. 559 — 69.

Grinevich V. B., Kravchuk, A.Yu., Tkachenko E. I. et al. Features of management of patients with gastroenterological pathology in the conditions of the COVID‑19 pandemic // Exp. Clin. Gastroenterol. — 2020. — 176 (4).

Gralnek I. M., Hassan C., Beilenhoff U. et al. ESGE and ESG NA Position Statement on gastrointestinal endoscopy and the COVID‑19 pandemic. Endoscopy. — 2020. — 52 (6). — P. 483 — 90.

Groves H. T., Higham S. L., Moffatt M. F., Cox M.J, Tregoning J. S. Respiratory viral infection alters the gut microbiota by inducing in appetence. MBio. 2020 Feb;11 (1):e03236 — 19.

Gu J., Han B., Wang J. COVID‑19: Gastrointestinal manifestations and potential fecal-oral transmission // Gastroenterology. — 2020. doi.org/10.1053/j.gastro.2020.02.054.

Gu S., Chen Y., Wu Z. et al. Alterations of the gut microbiota in patients with COVID‑19 or H1N1 influenza // Clin. Infect. Dis. 2020 Jun;ciaa709. Epub.

Han C., Duan C., Zhang S. et al. Digestive symptoms in COVID‑19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am. J. Gastroenterol. 2020 Jun;115 (6). — P. 916 — 23.

Hashimoto T., Perlot T., Rehman A. et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. — 2012. — 487 (7408). — P. 477 — 481.

Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS‑CoV‑2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. — 2020. 10.1016/j.cell.2020.02.052.

Jin X., Lian J.-S., Hu J.-H. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID‑19) with gastrointestinal symptoms // Gut. — 2020 gutjnl-2020 — 320926.

Kennedy N. A., Jones G. R., Lamb C. A. et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID‑19 pandemic // Gut. — 2020. — 69 (6). — P. 984 — 90.

Khan N., Patel D., Xie D. et al. Impact of anti-TNF and thiopurines medications on the development of COVID‑19 in patients with inflammatory bowel disease: a nationwide VA cohort study. Gastroenterology. Epub ahead of print 29 May 2020. doi: 10.1053/j.gastro.2020.05.065.

Lees C. W., Regueiro M., Mahadevan U. International Organization for the Study of Inflammatory Bowel Disease. Innovation in IBD care during the COVID‑19 pandemic: results of a global telemedicine survey by the international organization for the study of inflammatory bowel disease. Gastroenterology. Epub ahead of print 28 May 2020. doi: 10.1053/j.gastro.2020.05.063.

Lei P., Mi M., Pengcheng Y. et al., Clinical characteristics of COVID‑19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study // Am. J. Gastroenterol./ journals.lww.com/ajg/Documents/ COVID_Digestive_Symptoms_AJG_Preproof.pdf.

Li F., Lu H., Li X. et al. The impact of COVID‑19 on intestinal flora A protocol for systematic review and meta analysis Medicine (Baltimore). 2020 Sep 25. — 99 (39): e22273. Published online. 2020 Sep. 25. doi: 10.1097/MD.0000000000022273.

Ma C., Cong Y., Zhang H. COVID‑19 and the Digestive System // Am. J. Gastroenterol. — 2020. — 00. — P. 1 — 4. doi: 10.14309/ajg.0000000000000691.

Mao R., Qiu Y., He J. S., Tan J. Y., Li X. H., Liang J. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID‑19: a systematic review and meta-analysis // Lancet. Gastroenterol. Hepatol. — 2020. — 5 (7). — P. 667 — 678. doi: 10.1016/S2468-1253 (20)30126-6.

Monteleone G., Ardizzone S. Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? // J. Crohn’s Colitis. — 2020. — 14 (9). — P. 1334 — 6.

Morrow L. E., Kollef M. H., Casale T. B. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am. J. Respir. Crit. Care Med. — 2010. — 182 (8). — P. 1058 — 64.

Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev. Gastroenterol. Hepatol. — 2010. — 4 (3). — P. 261 — 70. doi: 10.1586/egh.10.25.38-4.

Nakase H., Matsumoto T., Matsuura M. et al. Expert opinions on the current therapeutic management of inflammatory bowel disease during the COVID‑19 pandemic: Japan IBD COVID‑19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research.

Nobel Y. R., Phipps M., Zucker J. et al. Gastrointestinal symptoms and coronavirus disease 2019: A case-control study from the United States // Gastroenterology. — 2020. — 159. — P. 373 — 375.e2.

Novak J. K. et al. Age, inflammation and disease location are critical determinants of intestinal expression of SARS‑CoV‑2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease // Gastroenterology. — 2020. — 12:S0016 — 5085 (20)30653 — 3.

Pan L., Mu M., Ren H. G. Clinical characteristics of COVID‑19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Practice Update. https://www.practiceupdate.com/content/clinical-characteristics-of-covid-19-patients-with-digestive-symptoms-in-hubei-china/98000.

Papa A., Papa V., Lopetuso L. R. et al. Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase // Therap. Adv. Gastroenterol. — 2020. — 13: Published online 2020 Oct 24. doi: 10.1177/1756284820968747.

Parasa S., Desai M., Thoguluva Chandrasekar V. et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis // JAMA. Netw. Open. — 2020 Jun;3 (6). — e201133.

Redd W. D., Zhou J. C., Hathorn K. E. et al. Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: A multicenter cohort study // Gastroenterology. — 2020. — 159. — P. 765.

Rubin D. T., Abreu M. T., Rai V.;On behalf of the International Organization for the STUDY OF INFLAMMATORY BOWEL DISEASE. Management of Patients with Crohn’s Disease and Ulcerative Colitis During the COVID‑19 Pandemic: Results of an International Meeting // Gastroenterology. — 2020. — doi:10.1053/j.gastro.2020.04.002.

Luo S., Zhang X., Xu H. Don’t Overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID‑19) // Clin. Gastroenterol. Hepatol. — 2020. — 18 (7). — P. 1636 — 1637. doi: 10.1016/j.cgh.2020.03.043.

Song Y., Liu P., Shi X. L. et al. SARS‑CoV‑2 induced diarrhea as onset symptom in patient with COVID‑19 // Gut. — 2020. — 69. — P. 1143 — 1144.

Sterne J. A. C., Murthy S., Diaz J. V. et al.; WHO Rapid Evidence Appraisal for COVID‑19 Therapies (REACT) Working Group/ Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID‑19: A Meta-analysis // JAMA. — 2020. — 324. — P. 1 — 13.

Sultan S., Altayar O., Siddique S. M. et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID‑19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID‑19 // Gastroenterology. — 2020. — 159. — P. 32.

Suresh Kumar V. C., Mukherjee S., Harne P. S. et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID‑19 // BMJ. — Open Gastroenterol. 2020 May;7 (1):e000417.

Tian Y., Rong L., Nian W., He Y. Review article: gastrointestinal features in COVID‑19 and the possibility of fecal transmission. Aliment. Pharmacol. Ther. 2020 May;51 (9). — P. 843 — 51.

Vuille-dit-Bille R. N., Camargo S. M., Emmenegger L. et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors // Amino Acids. — 2015. — 47 (4). — P. 693 — 705.

Wang C., Pan R., Wan X. et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID‑19) epidemic among the general population in China // Int. J. Environ. Res. Public. Health. — 2020. — 17 (5). — P. 1729.

Wu Y., Guo C., Tang L. et al. Prolonged presence of SARS‑CoV‑2 viral RNA in faecal samples // Lancet. Gastroenterol. Hepatol. — 2020. — 5. — P. 434 — 435.

Xiao F., Tang M., Zheng X. et al. Evidence for gastrointestinal infection of SARS‑CoV‑2 // Gastroenterology. — 2020. — 158. — 1831 — 1833. e1833.

Young B. E., Ong S. W. X., Kalimuddin S. Epidemiologic features and clinical course of patients infected with SArS- CoV-2 in Singapore // JAMA. — 2020 doi: 10.1001/jama.2020.3204.

Yeoh Y. K., Zuo T., Chung-Yan G. L. et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID‑19 // Gut. — 2021. — 0. — P. 1 — 9. doi: 10.1136/gutjnl-2020-323020.

Zuo T., Zhang F., Lui G. C. et al. Alterations in gut microbiota of patients with covid-19 during time of hospitalization // Gastroenterology. — 2020. — 159 (3). — P. 944 — 955. e8.

Lee I. C., Huo T. I., Huang Y. H. Gastrointestinal and liver manifestations in patients with COVID‑19 // J. Chin. Med. Assoc. — 2020. doi: 10.1097/JCMA.0000000000000319.

Greenhalgh T., Knight M., A’Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care // BMJ. — 2020. — Vol. 370. — m3026. doi: 10.1136/bmj.m30260319.

Geddes L. Why strange and debilitating coronavirus symptoms can last for months. New Scientist 2020.https://www.newscientist.com/article/mg24632881-400-why-strange-and-debilitating-coronavirus-symptoms-can-last-for-months/.

Sheehy L. M. Considerations for postacute rehabilitation for survivors of COVID‑19 // JMIR Public Health Surveill. — 2020. — Vol. 6. — e19462. doi: 10.2196/19462 pmid:32369030.

Corona Resource Centre [Electronic resource]. URL: https://coronavirus.jhu.edu/map.html (date of the application: 15.04.2021)

Téllez L., Martín Mateos RM. COVID‑19 and liver disease: An update // Gastroenterol. Hepatol. — 2020. — Vol. 43 (8). — P. 472 — 480. doi: 10.1016/j.gastrohep.2020.06.006.